Opioid Slider

We Cannot Treat the Dead

Assistant Scientist Amie Goodin, Ph.D., publishes an editorial in the American Journal of Public Health on the opioid epidemic.

Winterstein - ISPE President-Elect Slider

Dr. Winterstein installed as president-elect of the International Society for Pharmacoepidemiology

As president-elect, Almut Winterstein will serve on the executive board and chair the strategic planning committee. She joined ISPE in 2000 and has held numerous leadership roles during the past two decades.

Dr. Joshua Brown

Dr. Josh Brown receives NIH Loan Repayment Award and ambassador appointment

As a loan repayment awardee, Brown will receive financial support paying off his student debt, in return for a commitment to engage in NIH mission-relevant research.

Antibiotics Slider

Study finds that short-term use of azithromycin is not associated with increased risk of hearing loss

The researchers reviewed medical claims for around half million adults in 29 states who had used either azithromycin or amoxicillin during a 10 year period.

Ghadeer Dawwas

Diabetes, Obesity and Metabolism journal publishes grad student Ghadeer Dawwas’ SGLT2 inhibitors article

The study suggests that SGLT2 inhibitors are safe and effective in treatment of patients with type II diabetes.

Dr. Joshua Brown

Dr. Josh Brown appointed as associate editor of BMC Cardiovascular Disorders and Editorial Advisory Board of JMCP

These service appointments are the first for Brown, who joined the college in 2016.

Prev Next

Welcome to the Department of Pharmaceutical Outcomes and Policy

Thank you for your interest in our program. We are proud of our outstanding faculty, graduate students, fellows and staff who possess a passion and commitment to both teaching and research.

The Department of Pharmaceutical Outcomes and Policy includes a broad range of programs and resources. Faculty is actively engaged in the entry-level PharmD program and its own graduate program, including about 25 PhD students, a small number of residential and more than 150 online MS students.

alt text hereThe Department’s focus in research and graduate training is centered on the evaluation of drugs and related medical technology. This focus includes classic pharmacoepidemiologic and pharmacoeconomic work in areas such as drug safety and comparative effectiveness, as well as patient safety and program evaluation as related to medication use. We have excellent facilities for quantitative research including a data center with a state-of the art 32TB privacy-approved research server and a variety of billing record and clinical research databases.

UF Health, the largest fully integrated academic health center in the Southeast with all six health colleges on campus, allows broad interdisciplinary collaboration as well as access to a fully integrated electronic health record system. Our graduate program admits students each fall semester and we frequently offer fellowship and internship opportunities.

Almut G. Winterstein, Ph.D.
Department Chair

Meet Current POP Students


announcement graphic

POP Seminar Guest Speaker Announcement: Danielle N. Atkins, Ph.D.

The UF College of Pharmacy Department of Pharmaceutical Outcomes and Policy welcomes Danielle N. Atkins, Ph.D. as our October 11th Guest Speaker. Danielle Atkins, PhD is an Assistant Professor in the Department […]

Seminar announcement for Matthew Kirchoff

POP Seminar Guest Speaker Announcement: Matthew Kirchoff, PharmD, MS, MBA, CPH, BCPS

The UF College of Pharmacy Department of Pharmaceutical Outcomes and Policy welcomes Matthew Kirchoff, PharmD, MS, MBA, CPH, BCPS, as our October 4th Guest Speaker. Matthew Kirchoff, PharmD, MS, MBA, […]